Wall Street analysts predict that Sarepta Therapeutics Inc (NASDAQ:SRPT) will announce earnings of ($0.36) per share for the current quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Sarepta Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.56) and the highest estimate coming in at ($0.24). Sarepta Therapeutics reported earnings of ($1.58) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 77.2%. The business is expected to issue its next earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that Sarepta Therapeutics will report full year earnings of ($0.82) per share for the current fiscal year, with EPS estimates ranging from ($0.96) to ($0.71). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.95) per share, with EPS estimates ranging from ($1.58) to ($0.29). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Sarepta Therapeutics.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.66. The company had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same period in the previous year, the firm posted ($0.95) EPS.
Several brokerages have weighed in on SRPT. Leerink Swann reiterated an “outperform” rating and issued a $66.00 price target on shares of Sarepta Therapeutics in a report on Saturday, September 30th. HC Wainwright set a $75.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a report on Wednesday. Janney Montgomery Scott began coverage on Sarepta Therapeutics in a report on Wednesday. They issued a “buy” rating and a $75.00 price target for the company. Instinet reiterated a “buy” rating and issued a $84.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Finally, JPMorgan Chase & Co. reiterated a “hold” rating on shares of Sarepta Therapeutics in a report on Monday, September 25th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. Sarepta Therapeutics has a consensus rating of “Buy” and a consensus price target of $63.88.
In other Sarepta Therapeutics news, CEO Douglas S. Ingram purchased 38,138 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $52.44 per share, with a total value of $1,999,956.72. Following the transaction, the chief executive officer now owns 420,196 shares in the company, valued at $22,035,078.24. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $55.89, for a total transaction of $372,618.63. Following the sale, the director now directly owns 13,333 shares of the company’s stock, valued at $745,181.37. The disclosure for this sale can be found here. 9.60% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. boosted its position in Sarepta Therapeutics by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 271 shares during the period. Advisor Group Inc. boosted its position in Sarepta Therapeutics by 3.2% during the 2nd quarter. Advisor Group Inc. now owns 10,402 shares of the biotechnology company’s stock worth $351,000 after purchasing an additional 326 shares during the period. Legal & General Group Plc boosted its position in Sarepta Therapeutics by 3.9% during the 2nd quarter. Legal & General Group Plc now owns 17,590 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 663 shares during the period. Parametric Portfolio Associates LLC boosted its position in Sarepta Therapeutics by 0.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock worth $3,703,000 after purchasing an additional 818 shares during the period. Finally, C WorldWide Group Holding A S boosted its position in Sarepta Therapeutics by 0.8% during the 3rd quarter. C WorldWide Group Holding A S now owns 122,469 shares of the biotechnology company’s stock worth $5,555,000 after purchasing an additional 941 shares during the period. 82.02% of the stock is owned by hedge funds and other institutional investors.
Shares of Sarepta Therapeutics (NASDAQ SRPT) traded down $2.94 on Tuesday, reaching $54.87. The company’s stock had a trading volume of 3,099,900 shares, compared to its average volume of 1,450,000. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52. The firm has a market cap of $3,550.00, a P/E ratio of -26.90 and a beta of 1.37. Sarepta Therapeutics has a 52 week low of $26.26 and a 52 week high of $59.95.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.